Non-small cell lung cancer trial reports disappointing results
March 27th, 2008
The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) will not continue into a planned large study of a new drug for non-small cell lung cancer after its current phase of testing showed the drug’s side effects outweighed the benefits.